Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02208375 · ClinicalTrials.gov registry record · Phase 1

mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian

A Phase 1 study of Recurrent Ovarian Carcinoma and Recurrent Fallopian Tube Carcinoma, sponsored by M.D. Anderson Cancer Center.

Active
Registry status
Phase 1
Development phase
159
Enrollment target
1
Study location

NCT02208375 is a Phase 1 study of Recurrent Ovarian Carcinoma and Recurrent Fallopian Tube Carcinoma that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 159 participants, above the 120-participant average among 39 other Recurrent Ovarian Carcinoma trials with a reported enrollment target (33% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02208375, a Phase 1 study of Recurrent Ovarian Carcinoma and Recurrent Fallopian Tube Carcinoma, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
159 participants
Enrollment target
1
Study location

Study Summary

This phase Ib/II trial studies the side effects and best dose of olaparib and vistusertib (AZD2014) or olaparib and capivasertib (AZD5363) when given together in treating patients with endometrial, triple negative breast cancer, ovarian, primary peritoneal, or fallopian tube cancer that has come back (recurrent). Olaparib, vistusertib, and capivasertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Conditions Studied

Recurrent Ovarian Carcinoma Recurrent Fallopian Tube Carcinoma Recurrent Breast Carcinoma HER2/Neu Negative Estrogen Receptor Negative Progesterone Receptor Negative Endometrial Adenocarcinoma High Grade Ovarian Serous Adenocarcinoma BRCA1 Mutation Carrier BRCA2 Mutation Carrier

Interventions

  • OTHER Laboratory Biomarker Analysis
  • DRUG Olaparib
  • DRUG Capivasertib
  • OTHER Pharmacological Study
  • DRUG Vistusertib

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 159 participants
Start Date 2014-11-11
Est. Completion 2026-06-30
Phase Phase 1

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02208375

The ClinicalTrials.gov registry entry for NCT02208375 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 159 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 120-participant average among 39 other Recurrent Ovarian Carcinoma trials with a reported enrollment target (33% higher). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Recurrent Ovarian Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Laboratory Biomarker Analysis is the first listed.

NCT02208375 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT02208375 about?

NCT02208375 is a clinical study titled "mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian". This phase Ib/II trial studies the side effects and best dose of olaparib and vistusertib (AZD2014) or olaparib and capivasertib (AZD5363) when given together in treating patients with endometrial, triple negative breast cancer, ovarian, primary peritoneal, or fallopian tube cancer that has come bac...

What is the current status of trial NCT02208375?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 159 participants. The study started on 2014-11-11. Estimated completion is 2026-06-30.

What conditions does trial NCT02208375 study?

This clinical trial studies the following conditions: Recurrent Ovarian Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Breast Carcinoma, HER2/Neu Negative, Estrogen Receptor Negative.

What interventions are being tested in trial NCT02208375?

The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Olaparib (DRUG), Capivasertib (DRUG), Pharmacological Study (OTHER), Vistusertib (DRUG).

Who is sponsoring clinical trial NCT02208375?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02208375 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Recurrent Ovarian Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Recurrent Ovarian Carcinoma

All registered trials for this condition

Recurrent Fallopian Tube Carcinoma

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.